Chemed (NYSE:CHE) Stock Gets Price Target Bump from Oppenheimer

Chemed (NYSE:CHE) had its price objective raised by Oppenheimer from $590.00 to $625.00 in a report released on Thursday, Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Oppenheimer‘s price target indicates a potential upside of 16.88% from the company’s previous close.

A number of other equities analysts also recently weighed in on the stock. Jefferies Financial Group raised shares of Chemed from a “hold” rating to a “buy” rating and lifted their target price for the stock from $520.00 to $620.00 in a research note on Wednesday. Bank of America reaffirmed a “neutral” rating on shares of Chemed in a research report on Wednesday, July 29th. UBS Group assumed coverage on Chemed in a report on Friday, September 25th. They set a “buy” rating and a $650.00 price target for the company. Royal Bank Of Canada lifted their price objective on Chemed from $436.00 to $548.00 and gave the stock a “sector perform” rating in a research report on Thursday, July 30th. Finally, Wall Street Zen raised Chemed from a “buy” rating to a “strong-buy” rating in a research note on Saturday, October 10th. Three analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $590.60.

Chemed Stock Up 5.0%

Chemed stock opened at $534.72 on Thursday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.89 and a current ratio of 0.91. Chemed has a 52-week low of $365.20 and a 52-week high of $562.24. The firm has a 50 day moving average price of $514.55 and a two-hundred day moving average price of $462.04. The firm has a market cap of $6.99 billion, a price-to-earnings ratio of 26.86, a PEG ratio of 2.06 and a beta of 0.51.

Chemed (NYSE:CHE) last issued its quarterly earnings results on Tuesday, October 27th. The company reported $6.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.44 by $0.31. Chemed had a net margin of 10.60% and a return on equity of 31.77%. The firm had revenue of $690.94 million for the quarter, compared to the consensus estimate of $685.04 million. During the same quarter in the previous year, the company earned $5.27 EPS. The company’s revenue for the quarter was up 10.6% on a year-over-year basis. Equities analysts predict that Chemed will post 23.55 EPS for the current year.

Insider Transactions at Chemed

In other news, Director Patrick Grace sold 190 shares of the firm’s stock in a transaction dated Friday, July 31st. The stock was sold at an average price of $532.00, for a total value of $101,080.00. Following the completion of the sale, the director directly owned 3,533 shares in the company, valued at $1,879,556. This trade represents a 5.10% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Spencer Lee sold 1,000 shares of the firm’s stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $541.04, for a total value of $541,040.00. Following the completion of the sale, the executive vice president owned 13,912 shares of the company’s stock, valued at approximately $7,526,948.48. This represents a 6.71% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 9,190 shares of company stock valued at $4,833,160 in the last 90 days. 3.33% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in CHE. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of Chemed during the second quarter worth approximately $34,000. Versant Capital Management Inc grew its position in Chemed by 7,500.0% in the 2nd quarter. Versant Capital Management Inc now owns 76 shares of the company’s stock valued at $35,000 after purchasing an additional 75 shares during the period. Keating Financial Advisory Services Inc. acquired a new stake in Chemed in the 2nd quarter valued at $36,000. MassMutual Private Wealth & Trust FSB grew its position in Chemed by 65.3% in the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 81 shares of the company’s stock valued at $38,000 after purchasing an additional 32 shares during the period. Finally, Global Retirement Partners LLC bought a new stake in Chemed during the 2nd quarter valued at $49,000. Institutional investors own 95.85% of the company’s stock.

Key Chemed News

Here are the key news stories impacting Chemed this week:

• Positive Sentiment: Chemed exceeded third-quarter expectations: Adjusted EPS rose 28.1% year over year to $6.75, surpassing the $6.44 consensus estimate, while revenue increased 10.6% to $690.9 million versus expectations of $685.0 million. Chemed Reports Third-Quarter 2026 Results
• Positive Sentiment: VITAS delivered strong operating momentum: Hospice revenue increased 12.2% to $457.4 million, average daily census grew 9.4% to 24,428 and admissions increased 7.2%. Adjusted EBITDA excluding Medicare Cap rose 31.4%, with the margin expanding 318 basis points to 20.2%. Chemed Corp. Bottom Line Climbs in Q3
• Positive Sentiment: Management said full-year 2026 adjusted EPS should be at or slightly above the high end of the guidance issued in July, improving the outlook following the quarterly beat. Chemed Third-Quarter Revenue Rises 10.6%
• Positive Sentiment: Jefferies upgraded CHE to Buy, citing additional upside potential, while BofA raised its price target to $555 from $550 and maintained a Buy rating. Jefferies Upgrade and Price Target
• Neutral Sentiment: Chemed repurchased approximately 125,000 shares for $66 million and spent about $62.5 million to reacquire California Roto-Rooter franchise territories, supporting long-term growth but reducing near-term cash balances. Chemed Earnings Results
• Negative Sentiment: Roto-Rooter results were comparatively soft: Revenue grew 7.5% to $233.5 million, but segment net income declined 1.8%, adjusted EBITDA fell 2.5% and the margin contracted 213 basis points to 20.6%. Chemed Segment Results
• Negative Sentiment: Recent reported insider activity showed selling by executives, including CEO Kevin McNamara, with no disclosed insider purchases; this may modestly temper sentiment despite the strong operating results. Chemed Insider Activity

Chemed Company Profile

Chemed Corporation (NYSE:CHE) is a Cincinnati, Ohio-based company that provides healthcare and residential and commercial services through two operating businesses: VITAS Healthcare and Roto-Rooter. Its operations serve customers primarily in the United States, with Roto-Rooter also providing services in Canada.

VITAS Healthcare is a provider of hospice and palliative care for individuals with advanced illnesses. The business delivers care in patients’ homes, hospice inpatient units, hospitals, nursing facilities and other care settings.